Stereotaxis Robotic Technology Reduces Incidence of Silent Cerebral Embolism During Atrial Fibrillation Ablation in New Peer-Reviewed Publication

Rhea-AI Summary

Stereotaxis (NYSE: STXS) has announced a new publication demonstrating the effectiveness of its Robotic Magnetic Navigation (RMN) technology in reducing silent cerebral embolism (SCE) during atrial fibrillation ablation procedures. A study of 166 patients found that RMN significantly decreased SCE incidence to 5.77%, compared to 32.26% with manual catheters (p<0.001). This pivotal research, conducted independently in China, could position Stereotaxis as a leader in improving patient safety in cardiac interventions, reinforcing the efficacy of robotic solutions in complex procedures.

Positive

• Stereotaxis' RMN technology shows an 82% reduction in silent cerebral embolism incidence during atrial fibrillation ablation.
• The study reinforces the safety and efficacy of robotic technology in cardiac interventions.

Negative

• None.

ST. LOUIS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in Frontiers in Cardiovascular Medicine titled “Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism.”

This multi-center, prospective study evaluated 166 patients with paroxysmal or persistent Atrial Fibrillation (AF) who underwent pulmonary vein isolation using either Stereotaxis’ Robotic Magnetic Navigation (RMN) technology or manual contact force ablation catheters. All patients received cerebral magnetic resonance imaging within 48 hours before and after the ablation procedure to assess cerebral embolism. Patients treated using RMN had greater than 82% reduced incidence of silent cerebral embolism (SCE) at 5.77% compared to 32.26% in patients treated with manual catheter ablation (p<0.001). The study concluded, “ablation technology is the only independent risk factor of SCEs, and RMN can significantly reduce the incidence of SCEs resulting from AF ablation.” This is the first study comparing incidence of SCEs following cardiac ablation with RMN compared to manual catheters and was performed independent of Stereotaxis in China by Wuxi People’s Hospital, Fuwai Hospital, Xuzhou Central Hospital, and the First Hospital Affiliated to Soochow University.

“The results of this study further strengthen the significant safety and efficacy benefits we have experienced using robotic technology to treat over 600 arrhythmia patients,” said Dr. Ru-Xing Wang, Director of Cardiology at Wuxi People’s Hospital. “We are grateful to offer our patients the best possible care and look forward to advance clinical research and robotic technology development.”

“This pioneering research on an often overlooked aspect of cardiac ablation demonstrates that technology innovation can meaningfully improve patient safety,” said Dr. Yan Yao, Director of the Arrhythmia Center at Fuwai Hospital. “This strong data supports our decision to build a world-class robotic cardiac center of excellence in Beijing.”

Stereotaxis’ Robotic Magnetic Navigation technology introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Multiple studies have demonstrated reduced incidences of heart perforation and other major adverse events from the use of robotics for cardiac ablation when compared to manual hand-held catheters. This is the first study assessing the impact of robotics on silent cerebral emboli. Studies have demonstrated that incurring acute cerebral lesions during cardiac ablation procedures may be associated with longer-term adverse neuropsychological outcomes such as an increased risk of stroke and cognitive impairment.

The full publication can be found at https://www.frontiersin.org/articles/10.3389/fcvm.2021.777355/full. To access a complete database of more than 400 scientific publications referencing Stereotaxis technology, visit www.RoboticEP.com/clinical-data/publications-database/.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
investors@stereotaxis.com

FAQ

What is the latest study about Stereotaxis' technology published in Frontiers in Cardiovascular Medicine?

The study evaluates the effectiveness of Stereotaxis' Robotic Magnetic Navigation (RMN) technology in reducing silent cerebral embolism during atrial fibrillation ablation.

How much does Robotic Magnetic Navigation reduce silent cerebral embolism in patients?

RMN technology reduces silent cerebral embolism incidence to 5.77%, compared to 32.26% with manual catheters, representing over 82% reduction.

What was the sample size of the study evaluating Stereotaxis' technology?

The study included 166 patients undergoing atrial fibrillation ablation.

What significant benefits does RMN technology provide according to the study?

The study concludes that RMN technology significantly reduces the incidence of silent cerebral embolism, improving patient safety during cardiac procedures.

What impact does this study have on Stereotaxis' market position?

The favorable results may enhance Stereotaxis' reputation as a leader in innovative robotic technologies for cardiac care.